Abstract
The success of aggressive, curative anticancer therapies in pediatric oncology is possible only with intensive supportive-care measures. For example, antimicrobial prophylaxis can reduce infection rates in children undergoing myelosuppressive chemotherapy. Likewise, preemptive, broad-spectrum antibiotic therapy given as treatment for fever and neutropenia has been shown to reduce the mortality rate in this patient population. Furthermore, blood-product support is essential during periods of marrow suppression, and hematopoeitic growth factors, such as granulocyte colony-stimulating factor and erythropoietin, can be used to reduce the duration of pancytopenia. These interventions work together with therapeutic interventions to provide optimal outcomes for pediatric patients with cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Readings
Alexander SW, Wade KC, Hibberd PL, et al. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2002;24:38–42.
Alexander SW, Walsh TJ, Freifeld AG, et al. Infectious complications. In: Pizzo PA, Poplack DG, eds. Pediatric Cancer Patients in Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott, Williams and Wallace; 2002:1239–1283.
Baorto EP, Aquino VM, Mullen CA, et al. Clinical parameters associated with low bacteremia risk in 100 pediatric oncology patients with fever and neutropenia. Cancer 2001;92:909–913.
Buyukpamukcu M, Varan A, Kutluk T, et al. Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Med Pediatr Oncol 2002;39:455–458.
Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730–751.
Klaassen RJ, Goodman TR, Pham B, et al. “Low-risk” prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000;18:1012–1019.
Kocak U, Rolston KV, Mullen CA. Fever and neutropenia in children with solid tumors is similar in severity and outcome to that in children with leukemia. Support Care Cancer 2002;10:58–64.
Mullen CA, Petropoulos D, Roberts WR, et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. J Pediatr Hematol Oncol 1999;21:212–218.
Mullen CA, Petropoulos D, Roberts WR, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999;86:126–134.
Mullen CA. Which children with fever and neutropenia can be safely treated as outpatients? Br J Haematol 2001;112:832–837.
Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol 2002;39:77–85.
Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 2002;42:1398–1413.
Rossetto CL, McMahon JE. Current and future trends in transfusion therapy. J Pediatr Oncol Nurs 2000;17:160–173.
Ruggiero A, Riccardi R. Interventions for anemia in pediatric cancer patients. Med Pediatr Oncol 2002;39:451–454.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Rodriguez Cruz, N.I., Madden, R.M., Mullen, C.A. (2005). Supportive Care: Myelosuppression. In: Chan, K.W., Raney, R.B. (eds) Pediatric Oncology. M.D. Anderson Cancer Care Series, vol 4. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-24472-3_15
Download citation
DOI: https://doi.org/10.1007/978-0-387-24472-3_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24470-9
Online ISBN: 978-0-387-24472-3
eBook Packages: MedicineMedicine (R0)